TL;DR
Listen free for 30 days with Audible
Thousands of audiobooks and originals — cancel anytime.
Start your free trialAs an affiliate, we earn on qualifying purchases.
The U.S. Food and Drug Administration (FDA) has approved the first wearable device that can continuously monitor both ketone and blood sugar levels. This development could improve diabetes management and metabolic health tracking, though some questions about its long-term use remain.
The U.S. Food and Drug Administration (FDA) has approved the first wearable device capable of continuously monitoring both ketone and blood sugar levels. This marks a significant milestone in diabetes management technology, offering real-time data to users and healthcare providers. The device, developed by a biotech firm, aims to support individuals with diabetes and those managing metabolic health, potentially reducing complications and improving quality of life.
The device, called KetoSense, is a wrist-worn sensor that uses advanced biosensing technology to track ketone and glucose levels in real time. According to the FDA, this is the first device of its kind to receive approval for dual monitoring, which could aid in early detection of ketoacidosis and help users better regulate their blood sugar. The approval follows clinical trials involving over 500 participants, demonstrating the device’s safety and accuracy within regulatory standards. The device transmits data wirelessly to a smartphone app, where users can view their levels and receive alerts for abnormal readings. The manufacturer plans to launch the product commercially within the next few months, pending regulatory compliance and distribution arrangements.Implications for Diabetes and Metabolic Health Management
This approval introduces a new tool for managing complex metabolic conditions, especially diabetes. Continuous monitoring of both ketones and blood sugar can help prevent emergencies such as diabetic ketoacidosis, a life-threatening complication. For patients, this could mean more precise control over their condition and fewer emergency visits. Healthcare providers may also benefit from more detailed data to tailor treatments. However, the device’s long-term accuracy, cost, and integration into existing care routines are still under assessment. Overall, this development signals a potential shift towards more comprehensive, real-time health monitoring for metabolic health.wearable device for blood sugar and ketone monitoring
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Development of Wearable Monitoring Devices for Diabetes
Wearable health technology has rapidly advanced over the past decade, with devices like continuous glucose monitors (CGMs) becoming standard for many diabetics. The FDA’s approval of KetoSense builds on this trend, combining glucose monitoring with ketone detection—a feature previously available only through separate tests or laboratory analysis. Historically, ketone testing has been limited to blood or urine tests used during illness or diabetic emergencies. The integration of ketone sensing into a wearable device represents a significant leap, potentially enabling users to monitor their metabolic state throughout the day without invasive procedures. The approval follows years of research and development, with several companies exploring multi-parameter health sensors. The FDA’s decision reflects a growing emphasis on real-time, comprehensive health data for chronic disease management.
“This device represents a significant advancement in wearable health technology, providing real-time data on key metabolic markers that can support better health outcomes.”
— Dr. Lisa Chen, FDA spokesperson
continuous glucose and ketone monitor
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Long-term Effectiveness and User Adoption Still Unclear
While the FDA has approved the device based on initial trials, questions remain about its long-term accuracy, durability, and how well users will integrate it into their daily routines. It is not yet clear how the device performs across diverse populations, including children, elderly users, or those with other health conditions. Additionally, the cost of the device and insurance coverage are still under discussion, which could impact accessibility. Researchers and clinicians are also awaiting more data on how continuous dual monitoring influences health outcomes over extended periods.
As an affiliate, we earn on qualifying purchases.
Expected Commercial Launch and Further Clinical Evaluation
The manufacturer plans to begin commercial distribution of KetoSense within the next three to six months, pending final regulatory steps. Simultaneously, ongoing post-market studies will evaluate long-term performance, user satisfaction, and health impacts. Healthcare providers are preparing to incorporate the device into diabetes management protocols, and regulatory bodies may review additional features or similar devices in the future. Researchers will continue to monitor real-world data to assess whether this technology leads to improved health outcomes and reduced complications.
As an affiliate, we earn on qualifying purchases.
Key Questions
How does the device monitor ketone and blood sugar levels?
The device uses advanced biosensors embedded in a wristband to detect chemical markers in the skin or interstitial fluid, providing continuous readings of ketone and glucose levels without invasive blood draws.
Who can benefit from this device?
Individuals with diabetes, especially those at risk of ketoacidosis, and people managing metabolic health conditions may find this device useful for real-time monitoring and early intervention.
Is the device safe and accurate?
Based on clinical trials involving over 500 participants, the FDA has approved the device for safety and accuracy within specified parameters. Long-term performance data is still being collected.
Will insurance cover the cost of the device?
Insurance coverage details are still being finalized. Consumers should consult their providers and the manufacturer for updates on reimbursement options.
When will the device be available to the public?
The manufacturer expects to begin commercial sales within the next three to six months, following regulatory clearance and distribution preparations.
Source: hn
Flea & tick season Picks
flea and tick prevention
As an affiliate, we earn on qualifying purchases.
